Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ResMed (RMD)

ResMed Q3 fiscal 2025 revenue rises 8% to $1.3 billion; EPS up 22% to $2.48

Positive Impact 3 of 5 earnings Written later

ResMed reported results for the quarter ended March 31, 2025, with revenue up 8% to $1.3 billion and diluted EPS of $2.48, up from $2.04 a year earlier. The board also declared a $0.53 per share quarterly dividend, with a May 8, 2025 record date and a June 12, 2025 payment date.

Key points

  • Revenue $1,291.7 million, up 8% (9% constant currency); gross margin 59.3%, up 140 basis points
  • Income from operations $426.3 million, up 14%; net income $365.0 million, up 21%
  • Quarterly dividend of $0.53 per share; ex-dividend date May 7, 2025, payable June 12, 2025
  • Operating cash flow $579 million, including $107 million in IRS tax refunds

The filing

CompanyResMed (RMD)
Form8-K, current report
Filed with the SECApr 23, 2025, 4:05 PM ET
Accession number0001193125-25-091357

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 23, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.